Homocysteine enzymatic

Homocysteine enzymatic

A strong, independent risk factor for cardiovascular disease

  • Conventional risk factors, such as high cholesterol levels and high blood pressure, fail to account for all cases of cardiovascular disease (CVD). For example, more than 75 % of heart attacks occur in patients with normal cholesterol. 
  • Therefore, there is a clinical need to expand the number of diagnostic tools available for evaluating an individual’s risk of CVD. Numerous extensive studies have demonstrated that the concentration of homocysteine can serve as an excellent, clinically useful risk factor for CVD.
Homocysteine enzymatic
Assay time 10 min
Sample material Serum, plasma
Sample volume 14 uL
Measuring range 3 - 50 umol/L
Intermediate precision <2,3% (cobas c 501 module)
Systems cobas c 311 analyzer
cobas c 501/cobas c 502, cobas c 701/cobas c 702 module
COBAS INTEGRA™ 400 plus analyzer
COBAS INTEGRA 800 analyzer
MODULAR ANALYTICS <P>

Clinical benefit

homocysteine-chart

Predicted decrease in CVD risk following reduction in blood total homocysteine concentration. Whiskers represent the upper and lower 95 % confidence intervals for the calculated decrease in risk.

  • Measurement of homocysteine for cardiac risk patients under therapy has become an important diagnostic tool. Modest reduction of homocysteine levels is predicted to reduce the risk up to 25% for cardiovascular disease.
  • Roche Homocysteine is more specific than other methods because it does not interfere with cystathionine. Cystathionine levels are significantly elevated in millions of renal failure patients. Methods which are affected by this interference can overestimate homocysteine by as much as 20 – 300 %.

Benefits for the lab

  • The enzyme cycling test method is faster than High Performance Liquid Chromatography (HPLC) and immunoassays and does not require sample pre-treatment and special instrumentation.

Modest reduction of homocysteine is predicted to reduce the risk up to 25 % for cardiovascular disease.
Wald, D.S., Law, M., Morris, J.K. (2002). Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 325, 1202.

More than 75 % of heart attacks occur in patients with normal cholesterol.
Sachdeva, A., Cannon, C.P., Deedwania, P.C., Labresh, K.A., Smith S.C. Jr, Dai, D., Hernandez, A., Fonarow, G.C. (2009). Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines. Am Heart J 157, 111–117.

Numerous extensive studies have demonstrated that the concentration of homocysteine can serve as an excellent, clinically useful risk factor for CVD.

  • Refsum, H., Ueland, P.M., Nygard, O., Vollset, S.E. (1998). Homocysteine and cardiovascular disease. Annu Rev Med 49, 31–62.
  • Welch, G.N., Loscalzo, J. (1998). Homocysteine and atherothrombosis. N Engl J Med 338, 1042–1050.
  • Malinow, M.R., Bostom, A.G., Krauss, R.M. (1999). Homocyst(e)ine, diet, and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation 99, 178–182.
  • Refsum, H., Smith, A.D., Ueland, P.M., Nexo, E., Clarke, R., McPartlin, J., Johnston, C., Engbaek, F., Schneede, J., McPartlin, C., Scott, J.M. (2004). Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem 50, 3–32.
  • McCully, K.S. (2007). Homocysteine, vitamins, and vascular disease prevention. Am J Clin Nutr 86 (suppl), 1563–1568.